The Monopoly Stage of Capitalism

The changes to the current version of the Helsinki Declaration have led to fierce debate, particularly in the pharmaceutical industry and among drug regulators. The new version requires much greater openness: it requires that information about sources of funding or potential conflicts of interests b...

Full description

Saved in:
Bibliographic Details
Published inThe Hastings Center report Vol. 31; no. 3; p. 8
Main Author Nicholson, Richard H.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.05.2001
Hastings Center
Subjects
American Medical Association
Bioethics
Clinical trials
Clinical Trials as Topic - standards
Helsinki Declaration
Human Experimentation
Human experimentation in medicine
Human medical experimentation
Humans
International aspects
Laws, regulations and rules
Medical ethics
Medical research
Pharmaceutical industry
Self-experimentation in medicine
United States
United States Food and Drug Administration
United States
Online AccessGet full text

Cover

More Information
Summary:The changes to the current version of the Helsinki Declaration have led to fierce debate, particularly in the pharmaceutical industry and among drug regulators. The new version requires much greater openness: it requires that information about sources of funding or potential conflicts of interests be disclosed to IRBs and to subjects, that the design of all studies be publicly available and that the results of all studies be published or otherwise made publicly available, whatever the findings.
Bibliography:istex:D9A810F51476724D32B3AC379284EF4997576A9A
ArticleID:HAST938
ark:/67375/WNG-PMJ39TWL-W
SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:0093-0334
1552-146X
DOI:10.2307/3527548